|Mr. Kevin R. Lind||CFO & Exec. VP||697.88k||N/A||1976|
|Mr. Steven W. Spector||Exec. VP, Gen. Counsel & Sec.||731.24k||N/A||1965|
|Mr. Vincent E. Aurentz||Chief Bus. Officer & Exec. VP||785.9k||N/A||1968|
|Dr. Preston S. Klassen||Chief Medical Officer and Exec. VP of R&D||685.74k||N/A||1969|
|Mr. Amit D. Munshi||CEO, Pres & Director||N/A||N/A||1968|
Arena Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing novel small molecule drugs for various therapeutic areas in the United States and Switzerland. Its proprietary investigational clinical programs include ralinepag (APD811), which is in Phase III trial to treat pulmonary arterial hypertension; etrasimod that is in Phase II trials for treating immune and inflammatory conditions with primary focus on ulcerative colitis and hepatic conditions, as well as for primary biliary cholangitis and pyoderma gangrenosum; and APD371, which is in Phase II trial for the treatment of pain associated with Crohn's disease. The company has collaboration agreements with Everest Medicines Limited; Axovant Sciences GmbH; Boehringer Ingelheim International GmbH; Eisai Co., Ltd.; and Eisai Inc. Arena Pharmaceuticals, Inc. was founded in 1997 and is based in San Diego, California.
Arena Pharmaceuticals, Inc.’s ISS Governance QualityScore as of January 1, 2019 is 3. The pillar scores are Audit: 2; Board: 2; Shareholder Rights: 3; Compensation: 6.